ÂÜÀòÂÒÂ×

Mark Szczypka has a wealth of experience in the biotech industry, with roles ranging from President to Head of Emerging Therapies Services. Throughout their career, Mark has held leadership positions at companies such as Sartorius Stedim Biotech, Pall Corporation, SoloHill Engineering Inc., OncoImmune Inc., RenaMed Biologics, and the University of Washington. Mark's educational background includes a PhD in Biological Chemistry from the University of Michigan Medical School and a Bachelor's degree in Biology and Chemistry from Central Michigan University. Mark is known for their expertise in research, project execution, and obtaining extramural funding for programs within the biotech field.